These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 14607312)

  • 21. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
    J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.
    Panitch H; Goodin DS; Francis G; Chang P; Coyle PK; O'Connor P; Monaghan E; Li D; Weinshenker B; ;
    Neurology; 2002 Nov; 59(10):1496-506. PubMed ID: 12451188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.
    Hughes RA; Gorson KC; Cros D; Griffin J; Pollard J; Vallat JM; Maurer SL; Riester K; Davar G; Dawson K; Sandrock A;
    Neurology; 2010 Feb; 74(8):651-7. PubMed ID: 20177118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
    Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
    Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple sclerosis and depression: influence of interferon beta therapy.
    Zephir H; De Seze J; Stojkovic T; Delisse B; Ferriby D; Cabaret M; Vermersch P
    Mult Scler; 2003 Jun; 9(3):284-8. PubMed ID: 12814176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves.
    Liu C; Blumhardt LD
    J Neurol Neurosurg Psychiatry; 1999 Oct; 67(4):451-6. PubMed ID: 10486390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective baseline versus on-treatment study assessing patient perceptions of using a smaller needle when injecting intramuscular interferon beta-1 a (Avonex).
    Freedman SM; Cox D; Rosebrough T
    J Neurosci Nurs; 2008 Dec; 40(6):350-5. PubMed ID: 19170302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose titration of intramuscular interferon beta-1a reduces the severity and incidence of flu-like symptoms during treatment initiation.
    Matson MA; Zimmerman TR; Tuccillo D; Tang Y; Deykin A
    Curr Med Res Opin; 2011 Dec; 27(12):2271-8. PubMed ID: 21988668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b.
    Borràs C; Río J; Porcel J; Barrios M; Tintoré M; Montalban X
    Neurology; 1999 May; 52(8):1636-9. PubMed ID: 10331691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
    Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X
    J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two Multiple Sclerosis Quality-of-Life Measures: Comparison in a National Sample.
    Moore F; Vickrey B; Fortin K; Lee L
    Can J Neurol Sci; 2015 Jan; 42(1):55-63. PubMed ID: 25586701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Quality of life in patients with remitting-relapsing multiple sclerosis in Germany].
    Haupts M; Elias G; Hardt C; Langenbahn H; Obert H; Pöhlau D; Sczesni B; von Wussow P
    Nervenarzt; 2003 Feb; 74(2):144-50. PubMed ID: 12596015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rebif(®) Quality of Life (RebiQoL): A randomized, multicenter, Phase IIIb study evaluating quality-of-life measures in patients receiving the serum-free formulation of subcutaneous interferon beta-1a for the treatment of relapsing forms of multiple sclerosis.
    Bandari D; Wynn D; Miller T; Singer B; Wray S; Bennett R; Hayward B; Dangond F;
    Mult Scler Relat Disord; 2013 Jan; 2(1):45-56. PubMed ID: 25877454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: a double blind randomized clinical trial.
    Nafissi S; Azimi A; Amini-Harandi A; Salami S; shahkarami MA; Heshmat R
    Clin Neurol Neurosurg; 2012 Sep; 114(7):986-9. PubMed ID: 22429566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M;
    Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial.
    Lin X; Tench CR; Turner B; Blumhardt LD; Constantinescu CS
    J Neurol Neurosurg Psychiatry; 2003 Aug; 74(8):1090-4. PubMed ID: 12876240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality of life and its relationship to brain lesions and atrophy on magnetic resonance images in 60 patients with multiple sclerosis.
    Janardhan V; Bakshi R
    Arch Neurol; 2000 Oct; 57(10):1485-91. PubMed ID: 11030802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
    Arroyo González R; Kita M; Crayton H; Havrdova E; Margolin DH; Lake SL; Giovannoni G;
    Mult Scler; 2017 Sep; 23(10):1367-1376. PubMed ID: 27885061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-use autoinjector for once-weekly intramuscular injection of IFNβ-1a.
    Limmroth V; Gerbershagen K
    Expert Opin Drug Deliv; 2014 Dec; 11(12):1969-78. PubMed ID: 25255732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.